Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Century Therapeutics Inc.

    NASDAQ: IPSC · Real-Time Price · USD
    0.58
    -0.00 (-0.51%)
    At close: Jun 17, 2025, 11:35 AM
    -0.51%
    Bid 0.58
    Market Cap 50.4M
    Revenue (ttm) 114.9M
    Net Income (ttm) -21.95M
    EPS (ttm) -0.27
    PE Ratio (ttm) -2.17
    Forward PE -0.42
    Analyst Buy
    Ask 0.59
    Volume 166,257
    Avg. Volume (20D) 745,193
    Open 0.58
    Previous Close 0.58
    Day's Range 0.58 - 0.60
    52-Week Range 0.34 - 3.29
    Beta 1.77

    About IPSC

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol IPSC
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for IPSC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts
    news image

    1 week ago · zacks.com

    Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain

    Century Therapeutics (IPSC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several s...

    news image

    1 month ago · zacks.com

    Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates

    Century Therapeutics, Inc. (IPSC) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of a loss of $0.31 per share. This compares to loss of $0.45 per share a yea...

    news image

    1 month ago · zacks.com

    Century Therapeutics, Inc. (IPSC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

    Century Therapeutics (IPSC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    2 months ago · zacks.com

    Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock?

    Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    news image

    2 months ago · zacks.com

    Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates

    Century Therapeutics, Inc. (IPSC) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.49 per share a year ago.

    Add to Watchlist